G

GE Healthcare

Imaging, monitoring, and healthcare IT solutions

Verification Lead

Full-TimeUpdated on 10/15/2026
No salary listed
Mid
Bachelor's
Hino, Tokyo, Japan
In Person
QA & TestingManual & Functional QA

About the job

Requirements
  • A bachelor's degree in Engineering, Computer Science, Biomedical Engineering, Electrical Engineering, Mechanical Engineering, or a related technical discipline is required.
  • Significant experience in verification, validation, systems engineering, testing, or product development is required.
  • Experience developing verification plans, strategies, protocols, and reports is required.
  • Experience leading cross-functional technical activities in a product development environment is required.
  • A strong understanding of requirements management, traceability, defect management, and root cause analysis is required.
  • Demonstrated leadership, communication, and stakeholder management skills are required.
  • The ability to drive execution and influence outcomes across globally distributed teams is required.
  • Business-level Japanese proficiency is required for communication with local stakeholders and day-to-day operations in Japan.
  • Business-level English proficiency is required to collaborate with global teams and stakeholders.
Responsibilities
  • Own verification planning activities, including scope definition, resource planning, schedule alignment, and verification strategy development.
  • Lead feature, subsystem, and system-level verification activities throughout the product development lifecycle.
  • Ensure verification plans address product requirements, risk controls, and quality objectives.
  • Drive timely execution of verification cycles and support release readiness activities.
  • Review requirements for completeness, clarity, and testability.
  • Develop and maintain traceability between requirements, test cases, verification results, and defects.
  • Ensure adequate verification coverage and closure of verification deliverables.
  • Support risk assessments and mitigation activities, including FMEA and design reviews.
  • Serve as the primary verification focal point for assigned programs and initiatives.
  • Collaborate with Systems Engineering, Software Engineering, Program Leadership, and Quality teams to address technical risks and verification challenges.
  • Drive root cause investigations and resolution of complex verification issues.
  • Identify verification gaps, inefficiencies, and quality risks to influence product and process improvements.
  • Improve verification effectiveness, efficiency, and scalability through automation, standardization, and process optimization.
  • Promote best practices in test design, verification execution, documentation, and defect management.
  • Support adoption of data-driven metrics and AI-enabled productivity tools to improve verification performance.
  • Define and monitor verification performance indicators such as cycle time, automation coverage, defect trends, and verification efficiency.
  • Mentor and coach verification engineers on verification methodologies, systems thinking, problem solving, and technical best practices.
  • Facilitate alignment across global teams and stakeholders.
  • Coordinate verification activities across multiple programs and engineering functions.
  • Foster a culture of accountability, continuous learning, and operational excellence.
Desired Qualifications
  • Experience in medical device or regulated product development.
  • Experience supporting design controls, risk management, and product verification processes.
  • Experience with test automation, scripting, and verification productivity tools.
  • Experience with Agile and/or SAFe development methodologies.
  • Experience with systems integration and multi-disciplinary product development.
  • Knowledge of data analytics and AI-enabled engineering tools.
  • Experience leading continuous improvement initiatives focused on quality, productivity, or speed-to-market.

About the company

GE Healthcare Systems provides medical technologies and digital infrastructure to improve diagnosis, treatment, and monitoring of patients. Its products include imaging systems, mobile diagnostic devices, patient monitoring tools, and healthcare IT software that work together as hardware, software, and services to support hospitals, clinics, and researchers. The company differentiates itself with a large, integrated ecosystem, strong focus on AI analytics, and a global service network backed by substantial R&D investment. Its goal is to improve patient outcomes and the efficiency of healthcare delivery by enabling accurate diagnoses, effective treatments, and scaled operations.

Company Size

1-10

Company Stage

IPO

Headquarters

Chicago, Illinois

Founded

1892

Get referred to GE Healthcare

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 orders rose 11% and backlog reached a record $23.9 billion.
  • CareIntellect for Operations launched September 2026 with Duke Health and Queen's Health Systems.
  • CE mark and FDA progress for Photonova Spectra expand 2026-2027 commercial momentum.

What critics are saying

  • FDA logged multiple 2026 Class 2 recalls, including AW Server and telemetry systems.
  • Patient Care Solutions remained weak in Q2 2026; management is reviewing a sale.
  • SOFIE closes only after 2027 regulatory approvals; PET supply integration can slip badly.

What makes GE Healthcare unique

  • GE HealthCare combines imaging hardware, radiopharmaceuticals, and workflow software across hospitals.
  • Photonova Spectra and Vivid 2026 show premium innovation plus AI-enabled clinical automation.
  • SOFIE's 21 cyclotrons extend GE HealthCare into radiotracer manufacturing, not just scanners.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Tuition Reimbursement

Relocation Assistance

Company News

Business Wire
Oct 5th, 2026
GE HealthCare to acquire SOFIE Biosciences for $945M to expand US radiopharmaceutical supply

GE HealthCare has agreed to acquire SOFIE Biosciences, a US-based contract manufacturer of PET radiopharmaceuticals, for $945 million in cash. The deal with seller Trilantic North America is expected to close in the first half of 2027, subject to regulatory approvals. SOFIE Biosciences operates 15 contract manufacturing sites with 21 cyclotrons across the US, plus a theranostics-focused development and manufacturing facility. The acquisition establishes GE HealthCare's presence in the time-critical "final mile" of US PET radiopharmaceutical supply. The PET radiopharmaceutical market is expanding rapidly with approximately 20 PET radiotracers and over 30 radiotherapeutics currently under development. SOFIE Biosciences' portfolio includes a Phase III FAPI asset for which GE HealthCare already holds non-US rights. GE HealthCare estimates the transaction will be accretive to revenue growth, earnings margin, and earnings per share in the first full year of ownership.

PR Newswire
Sep 30th, 2026
AsiaMedic first in ASEAN to deploy GE HealthCare's MR31 deep learning MRI platform

AsiaMedic has become the first site in ASEAN to implement MR31, GE HealthCare's latest generation MRI platform featuring deep learning technology. The Singapore-based imaging centre is among the earliest adopters in Asia Pacific. MR31 incorporates deep learning technologies that reduce scan times and enable detailed examinations across neurological, musculoskeletal and nerve imaging. Sonic DL for 3D delivers up to 12 times scan acceleration, reducing examination times across brain, spine, orthopaedic and body scans. The platform also supports high-quality prostate MRI imaging. AIR Recon DL Phase Correction provides improved visualisation of clinically significant lesions, whilst high-resolution T2-weighted imaging aids lesion localisation for prostate fusion biopsy planning. Shorter scan times mean reduced patient time in scanners and may help decrease repeat examinations caused by movement.

Associated Press
Sep 22nd, 2026
GE HealthCare raises quarterly dividend 14% to $0.04 per share for Q3 2026

GE HealthCare Technologies announced a 14% dividend increase for the third quarter of 2026. The company's board declared a cash dividend of $0.04 per share, up from the previous quarter. The dividend will be paid on 13 November 2026 to shareholders of record as of 23 October 2026. GE HealthCare is a global healthcare solutions provider specialising in medical technology, pharmaceutical diagnostics, and AI-enabled software solutions. The company operates a $20.6 billion business with approximately 54,000 employees worldwide, serving the healthcare industry through its Advanced Imaging Solutions, Pharmaceutical Diagnostics, and Patient Care Solutions segments.

Yahoo Finance
Sep 15th, 2026
GE HealthCare launches AI tool to forecast hospital capacity bottlenecks 72 hours ahead

GE HealthCare has launched CareIntellect for Operations, an AI-powered software application that helps health systems forecast capacity constraints up to 72 hours ahead. The solution analyses hundreds of patient and operational data points to predict bottlenecks and recommend actions to optimise capacity and throughput. The Queen's Health Systems and Duke Health will be the first to implement the application. It uses two proprietary AI models: the Pressure Forecast model, which predicts resource constraints across hospitals and departments, and the Estimated Day of Discharge model, which predicts when patients will be discharged. The tool addresses operational challenges as US inpatient volumes rose 5.3% in 2025, requiring health systems to manage increased demand whilst facing staffing shortages and rising costs.

Yahoo Finance
Sep 1st, 2026
GE HealthCare secures CE mark for Photonova Spectra photon-counting CT system

GE HealthCare has received CE mark approval for its Photonova Spectra photon-counting computed tomography system, enabling commercial sales in markets recognising CE marking. The clearance follows US Food and Drug Administration approval and Japanese regulatory clearance in March 2026. The system uses GE HealthCare's Deep Silicon detector technology to deliver ultra-high definition spectral and spatial imaging. It processes data volumes up to 50 times greater than conventional CT systems, utilising Nvidia's accelerated computing platform. Clinical collaborations are underway at UZ Brussel in Belgium and Rigshospitalet in Denmark to evaluate the system across cardiology, neurology, oncology and musculoskeletal imaging. The CE mark follows more than $5 billion in innovation investment by GE HealthCare.